Natriuretic Peptides Assessment in Dilated Cardiomyopathy in Pati
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

Research Article - (2012) Volume 3, Issue 8

Natriuretic Peptides Assessment in Dilated Cardiomyopathy in Patients with Emery-Dreifuss Muscular Dystrophy

Irena M. Niebroj-Dobosz1*, Beata Sokolowska2, Agnieszka Madej-Pilarczyk1, Michal Marchel3 and Irena Hausmanowa-Petrusewicz1
1Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland
2Bioinformatics Laboratory, Mossakowski Medical Research Centre, Warsaw, Poland
31st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
*Corresponding Author: Irena M. Niebroj-Dobosz, Mossakowski Medical Research Centre, 5 Pawinskiego St, 02-106 Warsaw, Poland, Tel: +48(22)6086631 Email:


Introduction: Levels of natriuretic peptides in blood are often tested for as screening for heart disease and their progress assessed. Dilated cardiomyopathy (DCM) with conduction disturbances is one of the leading serious manifestations in genetically transmitted Emery-Dreifuss muscular dystrophy (EDMD). However, the potential significance of and variability to brain-natriuretic peptides (BNP) and atrial-natriuretic peptides (ANP) in this disease has not been tested hitherto. It seemed worth considering whether estimation of natriuretic peptides might help in defining cardiac dysfunction in the early stages of the disease, prior to the appearance of echocardiographic changes. This is perceived especially important in cardiologically asymptomatic patients, who are still at risk of cardiac sudden death. Patients and Methods: Serum levels of BNP, NT-proBNP, ANP and NT-proANP were quantified by ELISA sandwich immunoassay in 25 EDMD patients (10 autosomal-dominant AD-EDMD, 15 X-linked EDMD), 8 X-EDMD carriers, 9 patients with dystrophinopathy as disease controls, and 20 age-matched healthy controls. Results: Serum levels of BNP, NT-pro-BNP, ANP, and NT-proANP were elevated in the blood of about 50% of patients with both the AD-EDMD and the X-EDMD form. Values were distributed from normal through to highly elevated. In the X-EDMD group there was a marked increase in the ANP and NT-proANP values. The X-EDMD group also manifested a correlation between level of atrial natriuretic peptides, echocardiographic parameters and severity of cardiac symptoms. Conclusions: The presented results indicate that assessment of circulating natriuretic peptides is of limited value in identifying cardiac involvement in EDMD. However, when included to the panel of other cardiologic biomarkers the estimation of natriuretic peptides may offer additional information in respect of proper diagnosis, prognosis, monitoring of appropriate treatment, prediction of outcome. and help to prevent cardiac decompensation and sudden death.


AF: Atrial Fibrillation; VT: Ventricular Tachycardia; AFL: Atrial Flutter; SVT: Supraventricular Tachycardia; AVB: Atrio- Ventricular Block; ICD: Implanted Cardioverter/Defibrillator


It is a deficit of lamins A/C or emerin in skeletal muscle and heart muscle that causes the rare, genetically transmitted disease known as Emery-Dreifuss muscular dystrophy (EDMD). The cell defect is generalized, but skeletal muscles, heart and joints are selectively affected. The clinical symptoms of EDMD are manifested as skeletal muscle atrophy and weakness, joint contractures and dilated cardiomyopathy (DCM) with conduction disturbances. DCM remains clinically silent even for prolonged periods, but unexpected death in still young patients is not a rare event. The pathogenesis of DCM in EDMD is not recognized, as yet.

Several biomarkers of cardiovascular risk are the subject of constant investigation. Cardiac specific troponins, CK-MB, brain natriuretic peptides (BNP) and N-terminal pro-hormone brain natriuretic peptide (NT-proBNP) are often tested. Less frequently atrial natriuretic peptide (ANP) and N-terminal pro-hormone atrial natriuretic peptide (NTproANP) are examined. Generally there are greater or lesser reservations in regard to nearly all tested biomarkers, including natriuretic peptides. Assessment of the stage of the involvement and advancement of cardiac disease, control of its treatment and establishment of further prognosis with the aid of cardiovascular biomarkers is difficult and still under debate.

The aim of our study was to compare the diagnostic value of circulating BNP, ANP, NT-proBNP and NT-proANP in order to decide which of the commonly tested natriuretic peptides would be of value in cardiological practice and specifically in detecting cardiomyopathy in EDMD in order to prevent unexpected cardiac decompensation and sudden death, in cardiac asymptomatic patients in particular.

Materials and Methods


A total of 25 patients (19 males and 6 females) with EDMD were included in this study. Ten patients had autosomal-dominant EDMD associated with laminopathy (AD-EDMD), with one patient in this group being after heart transplantation (age 31 ± 4 years), 15 had X-linked EDMD (X-EDMD) associated with emerinopathy (age 28 ± 3 years), and 8 were X-EDMD carriers (age 37 ± 5 years). The diagnosis of AD-EDMD and X-EDMD was established clinically and confirmed genetically by reference to the genetic defect in the LMNA and EMD gene, respectively. The group of disease controls included 9 patients with Duchenne/Becker progressive muscular dystrophy (DMD/BMD). The diagnosis in these cases was based on clinical status, creatine kinase activity in blood and a lack/decrease of dystrophin expression noted on immunohistochemical/ immunochemical examination of skeletal muscles biopsy.

Cardiomyopathy was diagnosed in all the EDMD patients (Table 1). In the AD-EDMD group the progression of cardiac symptoms was either mild/moderate in 5 cases, severe/very severe in the other 5. Two patients died, and one patient who was not taken into account in the statistical calculations of natriuretic peptides was after heart transplantation. The cardiac parameters on echocardiography were out of the normal range in only two AD-EDMD patients. In 5 cases a pacemaker, while in a further 2a cardiac cardioverter-defibrillator had been implanted. In the X-EDMD group the cardiac involvement was either moderate (in 12 cases), or mild (in 3 cases). The echocardiographic parameters had been changed in 3 cases. A pacemaker was implanted in 12 of the 15 patients. Mild/moderate cardiac sympthomatology was also found in the X-EDMD carriers. In 2 of the 8 carriers pacemaker had been implanted. In the DMD/BMD group dilated cardiomyopathy was manifested as echocardiographic abnormalities, while in some patients severe heart failure symptoms were present. In neither of the EDMD groups was it a straightforward matter to track the development of cardiomyopathy. Even patients with evident bradycardia usually had their cardiac symptoms detected once the first neurological diagnosis of EDMD had been established. The control group consisted of 20 agematched normal subjects with no history of cardiac disease.

Description X-EDMD
X-EDMD carriers
Family history familial (14)
sporadic (1)
familial (7)
sporadic (3)
familial (8)
Age (yrs) 25 (18-36) 29 (22-31) 33 (28-51)
Skeletal muscle involvement elbow, ankle contractures and spine rigidity (15)
generalized muscle atrophy (3)
arms, calf atrophy (5)
arm atrophy (2)
elbow, ankle contractures and spine rigidity (9)
generalized atrophy (6)
arms, tights (2)
arms, calf atrophy (1)
wheelchair-bound (2)
no skeletal muscle involvement
Cardiac symptoms AVB 2/3 (7)
AF/AFL (5)
tachy-brady (3)
heart failure (3)
(including NYHA III (1), NYHA II/III (2)
AVB 3 (3)
AF (4)
SVT (3)
VT (1)
AVB 2/3 (2)
Cardiac device/age of implantation pacemaker/14-33 yrs) (11) Pacemaker/20-41 yrs (5), then ICD/28-29yrs (2 of these 5) Pacemaker/42-44 yrs (2)
Mutation 1A>G (2)
3G>A (1)
153delC (6)
192G>T, 194insC (1)
256C>T (1)
266-27del18 (1)
397C>T (1)
399+1G>C (1)
450insG (1)
334_336del (1)
788T>C (1)
743T>C (1)
1072G>A (1)
1337A>T (1)
1357C>T (4)
153delC (4)
399+1G>C (2)
450insG (2)
CK-MB (%) A 3.2 (2.6-6.4) (n=11) 3.4 (2.5-7.7) (n=7) 9.9 (2.0-10.5) (n=5)
Values are presented as medians and interquartile ranges
Number of patients is shown in parentheses
A Values in normals: 2.2 (0.0-2.8) (n=20)
Abbreviations: AF - atrial fibrillation; VT - ventricular tachycardia; AFL - atrial flutter; SVT - supraventricular tachycardia; AVB atrio-ventricular block; ICD - implanted

Table 1: Summary of clinical and laboratory data in patients with Emery-Dreifuss muscular dystrophy

Skeletal muscle atrophy in AD-EDMD was mild in 2 cases, moderate in 4 and severe/very severe in further 4. In X-EDMD skeletal muscle atrophy was present in 12 cases, being either mild/moderate, or severe (3 cases).

Analytical measurements

Blood was collected for routine biochemical analyses, and centrifuged at 3000 rpm for 10 minutes. Serum was separated and frozen at -30°C until used. The level of the biomarkers was determined using an ELISA sandwich enzyme immunoassay for BNP, ANP and NTproBNP using the USCN Life Science INC kit, to test for NT-proANP a Biomedica Gruppe kit was used. Absorbance at 450 nm was assessed using a Sigma Diagnostics EIA Microwell Reader II.

Statistical analyses

The analysis was performed using a commercial statistical program (Statistica 5, StatSoft, Poland). The medians and interquartile ranges are presented, because data distributions were non-normal. Use was made of analysis of variance on ranks with the Kruskal-Wallis test. Differences in variable values were assessed using the Mann-Whithney U test, while the relationships between variables were analyzed using Spearman’s correlation coefficient (ρ). The ROC analysis was also included. The p<0.05 value was considered to be statistically significant.


Serum levels of different natriuretic peptides were significantly elevated in the EDMD patients, through values were distributed across a wide range-from normal to highly elevated in both EDMD forms (Table 2). An elevated level of ANP and NT-proANP appeared more often in X-EDMD, as compared with the AD-EDMD group (Figure 1). To assess the usefulness of natriuretic peptides levels estimation in diagnostics the areas under the ROC curves and (AUC) were calculated (Figure 2 and 3). It is indicated that both the sensitivity and specificity of natriuretic peptides, although limited, allows for the detection of the disease status in some of the EDMD patients. In the X-linked EDMD patients there was a significant correlation between BNP and ANP (ρ=0.77, p=0.003), ANP and LVDD (ρ=0.73, p=0.016), NT-proANP and LVDD (ρ=-0.69, p=0.014) and NT-proANP and LAD (ρ=-0.71, p=0.006). In 8 X-EDMD carriers certain values were raised (in 4 for BNP, in 5 for NT-pro-BNP, in 1 for ANP, and in 2 for NT-proANP). Very much raised values for all natriuretic peptides were present in all cases with dystrophinopathies, also the asymptomatic ones (in five of the nine examined) (Table 2). Raised natriuretic peptides were detected also in carriers of X-EDMD (in two of the eight tested). Values for natriuretic peptides did not correlate with age. A correlation with the severity of cardiac symptoms was observed when atrial natriuretic peptides were assessed. The results were at the threshold of significance in AD-EDMD (ρ=0.55, p=0.050), while in X-EDMD the correlation achieved significance (ρ=0.65, p=0.023).


Figure 1: Percentage of changed values of serum natriuretic peptides in EDMD.


Figure 2: Receiver operatinag characteristics (ROC) analysis of serum concentrations of BNP and NT-proBNP in EDMD patients.


Figure 3: Receiver operating characteristics (ROC) analysis of serum concentrations of ANP and NT-proANP in EDMD patients.

Groups BNP
AD-EDMD 42 (18-54) *,# 85 (17-195) * 273 (1.3-366) 0.50 (0.28-0.58) ##
X-EDMD 24 (6-105) # 53 (14-192) 366 (0.9-391) 0.54 (0.37-0.60) ##
X-EDMD carriers 22 (9-62) 87 (33-400) 8.1 (0.9-8.1) 0.34 (0.29-0.65)
Dystrophinopathies 163 (50-337) *** 103 (9-457) * 344 (286-362) *** 2.5 (1.6-2.6) ***
Healthy controls 15 (9-20) 29 (15-49) 4.9 (2.3-5.6) 0.38 (0.32-0.42)
Medians and interquartile ranges are presented
* p<0.05, ** p<0.005, *** p<0.0005 for the patient groups vs. healthy controls
# p<0.05, ## p<0.005; AD-EDMD or X-EDMD patients vs. disease controls

Table 2: Natriuretic peptide concentrations in EDMD patients and controls


Several biomarkers of heart diseases of various etiologies are currently introduced in the cardiological practice. Detection of heart diseases in an early stage may arrest their progress, delay the development of serious heart failure symptoms, allow for the introduction of appropriate cardiological treatment and provide for predictions of cardiovascular mortality Among biomarkers brain natriuretic peptide (BNP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) are already accepted in respect of the early diagnosis and prognosis of left ventricular dysfunction [1]. It is also proposed that B-type natriuretic peptide is a strong prognostic indicator for both asymptomatic patients and those with heart failure at all stages of disease [2]. However, controversies about usefulness of natriuretic peptides in clinical practice exist, as their diagnostic credibility is still not settled. NT-proBNP is thought to be even more useful in screening for latent heart disease [3] and the earlier diagnosis of cardiac dysfunction as compared with BNP [4]. Although promising, atrial natriuretic peptide (ANP) and N-terminal prohormone atrial natriuretic peptide (NT-proANP) are so far seen as of more limited value, and still under debate.

The pathophysiological effects of natriuretic peptides are vasodilatation, natriuresis, inhibition of the rennin-angiotensinaldosteron system, a shift of fluids from intravascular into extravascular space, diuresis, inhibition of adrenergic stimulation, increase of intraglomular pressure and glomerular filtration, inhibition of sodium and water transport in proximal tubules and the blocking of sodium reabsorption. BNP exerts its action through high affinity receptors on the target cells and is stored mainly in the ventricular myocardium. In both healthy subjects, and patients with left ventricle dysfunction, BNP and NT-proBNP are secreted mainly from the left ventricle, but in small amounts also from the atria [5].

BNP and NT-proBNP are used currently by cardiologists as diagnostic biomarkers of heart failure [6], LV dysfunction [7], severity of heart failure, and as indicators of regional conditions and structural change in myocytes [8], the risk of cardiovascular events and death [9-12]. BNP assessment is also useful in predicting the longterm risk of redecompensation in non-ischemic DCM, even in lowrisk outpatients [13]. Its secretion is regulated by wall tension of the left ventricle and severity of heart failure [3,14], left ventricular wall thickness, left ventricular mass [15], ischemia caused by local hypoxia [16], local pH changes, the presence of arrhythmia, thrombosis of the pulmonary artery, and other factors of right ventricle dysfunction [16,17]. It improves diagnosis in acute dyspnea [9,18], gives prognostic information [2,13,19-23] and offers an evaluation of left-ventricular function and effectivness of therapy in congestive heart failure [24,25]. In chronic heart failure there is a correlation between BNP and NTproBNP with disease severity and prognosis [26]. In hypertrophic cardiomyopathy NT-proBNP and ANP are associated with severity of LV diastolic dysfunction and hypertrophy of LV, as well as of hemodynamic and functional disturbances [27]. BNP is suggested to be important in predicting sudden death in chronic heart failure and is an independent risk factor for heart failure events [28]. BNP is also indicated as a simple and useful marker in predicting of progressive ventricular remodeling within the first 30 days of acute myocardial infarction [29].

Serial determinations of BNP and ANP may provide for the recognition of hemodynamic deterioration [30]. Both can be used as simple clinical markers for risk stratification in congenital heart disease in adults [31] and chronic heart failure [32-34].

BNP in blood is also advocated in the study of Duchenne dystrophy with a view cardiac dysfunction either manifest or latent [35]. Data on BNP, NT-proBNP, ANP and NT-proANP in Emery-Dreifuss muscular were not published, yet.

NT-proBNP may be an alternative marker for the detection of left ventricle dysfunction [36] and it is even preferable to BNP for the detection of heart failure, when it comes to the detection of heart failure, especially in asymptomatic patients [4]. Its concentrations are more elevated in acute left ventricular dysfunction as compared with stable chronic DCM [37]. It is a good marker by which to discriminate patients for transplantation and prognosis and is a predictive marker for the consequences of treatment in chronic heart failure. Very high levels are found in patients who went on to die. A strong correlation has been noted between NT-proBNP and NYHA class and HFSS [38]. Cardiac fibrosis correlates with elevated NT-proBNP and left ventricular remodeling and diastolic function in patients with non-ischemic DCM [39]. Marked reductions in the level of NT-proBNP and also BNP are indicative of an improved outcome in chronic heart diseases [40].

From the set of BNP, NT-proBNP and NT-proANP used as screening tests for heart failure, BNP is indicated as the best marker to detect patients with impaired LVEF, and NT-proBNP might be an alternative marker of deteriorated cardiac function [36,41]. However, it needs to be kept in mind that increased BNP/NT-proBNP levels are not strictly specific for heart diseases [42] and that BNP and NT-proBNP are influenced by such extracardial factors as gender, age, glomerular filtration [43] and obesity [44]. Elevated NT-pro-BNP better predicts the risk of adverse events in long-term systolic dysfunction [45]. A combination of left atrial enlargement and high NT-proBNP increase the risk of sudden death [46]. BNP and NT-proBNP are indicated as superior to ANP and NT-proANP as diagnostic and prognostic markers in heart insufficiency [1].

ANP plays an important role in homeostasis of body fluids and blood pressure [47-49]. ANP is secreted from atria in normal humans and from the left ventricle in patients with left ventricle dysfunction, and correlates with the severity of left ventricle dysfunction [14] ANP is stored in atrial myocytes, its secretion being stimulated by atrial dilatation. In DCM ANP is also secreted from ventricles [50]. Blood ANP level is elevated in atrial fibrillation [51].

Blood levels of ANP like BNP correlate with hemodynamic parameters of patients with chronic heart failure. Relations between ventricular structure and secretion pattern of BNP and ANP point to differences in patients with idiopathic dilated cardiomyopathy and hypertrophic cardiomyopathy (HP). The levels of ANP and BNP are higher in DCM as compared with HP. The main factor determining the secretion of ANP as BNP is the intraventricular cavity size [52].

ANP is related positively to the clinical status and to the left ventricle dysfunction and dilatation [53], correlates with left ventricular dimensions [14], and reflects the severity of heart failure [54]. Successful cardioversion in persistent atrial fibrillation leads to ANP reduction [55]. Increase in plasma ANP concomitantly with BNP are sensitive markers confirming atrial standstill in the setting of congestive heart failure [56]. ANP is elevated in blood in various cardiac diseases, including valve diseases, coronary heart diseases and cardiomyopathy, where a linear relationship is found between mean pulmonary artery pressure and blood ANP concentration [28].

NT-proANP blood levels may be a more sensitive marker of left ventricular dysfunction than ANP [57]. It correlates with left atrial diameter, left ventricular ejection fraction and Doppler derived E/A ratio on transmitral inflow. In DCM there is a relation between NTproANP and systolic and diastolic parameters [58]. Both NT-proANP and ANP are elevated in patients with chronic heart failure and reflects the severity of heart failure [56]. NT-proANP is less variable than ANP and hence it is more suited for diagnostic and prognostic purposes [59]. It is elevated in cases with persistent atrial fibrillation [60] and is associated with increased cardiovascular risk [61].

Notwithstanding numerous reports and even introduction into clinical practice the diagnostic credibility of natriuretic peptides as biomarkers of heart diseases, despite numerous reports and their introduction in clinical practice, is limited. It should be kept in mind that there are several factors as several medicines should come [62], which could influence their level in the blood stream. Their concentration increases with of ages of patients and gender [62,63].

Biomarkers might be helpful in establishing of an early pharmacological treatment, in decisions regarding cardiac device implantation and in consideration of heart transplantation. As there are limitations caused by the influence of extracardial factors, a single biochemical marker accompanied by cardiological parameter assessments, cannot be treated as a definitive marker as regards the recognition of cardiomyopathy at an early stage, a decision relating to severity of the disease, the monitoring of treatment efficiency or the predicting of sudden death in these patients. By combining data from natriuretic peptides and other biomarkers testing as osteopontin [64], tenascin-C [65] and MMP-2 [66] it might be possible to develop an assay system with optimal diagnostic and prognostic significance, indicate potential therapeutic intervention and allow to start an early pharmacological resynchronizing therapy and/or implantation to start.


1) The value BNP and NT-pro-BNP estimation in regard to the detection rate for dilated cardiomyopathy in patients with AD-EDMD and X-EDMD is limited, as their concentration in serum in about half of all patients is normal.

2) A high level of ANP and NT-proANP and a correlation with echocardiographic parameters in the majority of X-EDMD cases might indicate atrial involvement as a primary cardiac defect in this form of EDMD.

3) The correlation between the atrial natriuretic peptides and the severity of the disease in cases of X-EDMD corresponds with the deteriorating function of atria over time.

4) Elevated level of natriuretic peptides is present also in dytrophinopathies, exceeding even the values present in EDMD, also in cardiologically asymptomatic patients and in the majority of the X-EDMD carriers.

5) Although the credibility of natriuretic peptides as cardiologic biomarkers in EDMD is limited, it is, however, worth to include them in the panel of cardiological tests. They may offer additional information in respect of proper diagnosis, prognosis, the commencement and monitoring of appropriate treatment, prediction of the outcome and help to prevent cardiac decompensation and sudden death.


The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw.


  1. Mair J, Friedl W, Thomas S, Puschendorf B (1999) Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 230: 132-142.
  2. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systemic review. BMJ 330: 625.
  3. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, et al. (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet 351: 9-13.
  4. Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2004) Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341: 41-48.
  5. Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, et al. (1991) Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 17: 1152-1155.
  6. Wu AH, Smith A (2004) Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6: 355-358.
  7. Alter P, Rupp H, Rominger MB, Vollrath A, Czerny F, et al. (2008) B-type natriuretic peptide and wall stress in dilated human heart. Mol Cell Biochem 314: 179-191.
  8. Tanaka M, Hiroe M, Nishikawa T, Sato T, Marumo F (1994) Cellular localization and structural characterization of natriuretic peptide-expressing ventricular myocytes from patients with dilated cardiomyopathy. J Histochem Cytochem 42: 1207-1214.
  9. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167.
  10. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, et al. (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106: 2913-2918.
  11. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, et al. (2002) Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 87: 131-135.
  12. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al. (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350: 655-663.
  13. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, et al. (2008) Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 51: 2329-2335.
  14. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203.
  15. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, et al. (2001) Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 51: 585-591.
  16. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA (2003) B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul Study. Circulation 108: 2987-2992.
  17. Torbicki A, Pruszczyk P, Kurzyna M (2005) Pulmonary embolism: role of echocardiography and of biological markers. Ital Heart J 6: 805-810.
  18. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, et al. (2002) Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39: 202-209.
  19. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, et al. (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37: 386-391.
  20. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, et al. (2001) Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 65: 155-160.
  21. Tamura K, Takahashi N, Nakatani Y, Onishi S, Iwasaka T (2001) Prognostic impact of plasma brain natriuretic peptide for cardiac events in elderly patients with congestive heart failure. Gerontology 47: 46-51.
  22. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, et al. (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43: 635-641.
  23. Verdiani V, Nozzoli C, Bacci F, Cecchin A, Rutili MS, et al. (2005) Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 7: 566-571.
  24. Yamada Y, Goto J, Yokota M (1997) Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 88: 401-407.
  25. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M (2001) Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141: 925-932.
  26. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362: 316-322.
  27. Safrygina IuV, Gabrusenko SA, Ovchinnikov AG, Masenko VP, Naumov VG, et al. (2007) [Cardiac natriuretic peptides in patients with hypertrophic cardiomyopathy]. Kardiologiia 47: 50-57.
  28.  Lang RE, Dietz R, Merkel A, Unger T, Ruskoaho H, et al. (1986) Plasma atrial natriuretic values in cardiac disease. J Hypertens Suppl 4: S119-S123.
  29. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, et al. (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135: 21-28.
  30. Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, et al. (2007) Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Card Fail 13: 380-388.
  31. Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, et al. (2010) Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 105: 869-873.
  32. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, et al. (1991) Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84: 1581-1588.
  33. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, et al. (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469.
  34. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, et al. (1993) Natriuretic peptide system in human heart failure. Circulation 88: 1004-1009.
  35. Kashiwagi S, Akaike M, Kawai H, Adachi K, Saito S (1996) [Estimation of cardiac function by plasma concentration of brain natriuretic peptide in patients with Duchenne muscular dystrophy]. Rinsho Shinkeigaku 36: 7-11.
  36. Hammerer-Lercher A, Neubauer E, Müller S, Pachinger O, Puschendorf B, et al. (2001) Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310: 193-197.
  37. Friedl W, Mair J, Thomas S, Pichler M, Puschendorf B (1996) Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 76: 129-136.
  38. Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, et al. (2004) Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 23: 1189-1197.
  39. Karaahmet T, Tigen K, Dundar C, Pala S, Guler A, et al. (2010) The effect of cardiac fibrosis on left ventricular remodeling, diastolic function, and N-terminal pro-B-type natriuretic peptide levels in patients with nonischemic dilated cardiomyopathy. Echocardiography 27: 954-960.
  40. Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS (2009) Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 55: 78-84.
  41. Sagnella GA (2001) Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 38: 83-93.
  42. Angermann CE, Ertl G (2004) [Natriuretic peptides--new diagnostic markers in heart disease]. Herz 29: 609-617.
  43. McCullough PA, Duc P, Omland T, Mc Cord J, Nowak RM, et al. (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure. An analysis from Breathing not Properly Multinational Study. Am J Kidney Dis 41: 571-579.
  44. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, et al. (2004) Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164: 2247-2252.
  45. Limongelli G, Pacileo G, Ancona R, Eusebio G, D'Andrea A, et al. (2010) Clinical course and risk profile in adolescents with idiopathic dilated cardiomyopathy. Am J Cardiol 105: 716-720.
  46. Bayes-Genis A, Vazquez R, Puig T, Fernandez-Palomeque C, Fabregat J, et al. (2007) Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail 9: 802-807.
  47. Laragh JH (1985) Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 313: 1330-1340.
  48. Needleman P, Greenwald JE (1986) Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N Engl J Med 314: 828-834.
  49. Ballermann BJ, Brenner BM (1986) George E. Brown memorial lecture. Role of atrial peptides in body fluid homeostasis. Circ Res 58: 619-630.
  50. Yasue H, Obata K, Okumura K, Kurose M, Ogawa H, et al. (1989) Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest 83: 46-51.
  51. Schiffrin EL, Gutkowska J, Kuchel O, Cantin M, Genest J (1985) Plasma concentration of atrial natriuretic factor in a patient with paroxysmal atrial tachycardia. N Engl J Med 312: 1196-1197.
  52. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, et al. (2000) Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86: 1036-1040.
  53. Arbustini E, Pucci A, Grasso M, Diegoli M, Pozzi R, et al. (1990) Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment. Am J Cardiol 66: 973-980.
  54. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, et al. (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145-1147.
  55. Wozakowska-Kapłon B, Opolski G, Janion M (2003) Atrial natriuretic peptide before and after cardioversion of persistent atrial fibrillation. Kardiol Pol 58: 255-263.
  56. Suguta M, Hara K, Nakano A, Amano A, Hasegawa A, et al. (2000) Serum atrial natriuretic peptide concentration is a useful predictor of atrial standstill in patients with heart failure. Jpn Circ J 64: 537-540.
  57. Azizi C, Maistre G, Kalotka H, Isnard R, Barthélemy C, et al. (1996) Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 148: 51-57.
  58. Fruhwald FM, Fahrleitner A, Watzinger N, Dobnig H, Schumacher M, et al. (1999) N-terminal proatrial natriuretic peptide correlates with systolic dysfunction and left ventricular filling pattern in patients with idiopathic dilated cardiomyopathy. Heart 82: 630-633.
  59. McDowell G, Patterson C, Maguire S, Shaw C, Nicholls DP, et al. (2002) Variability of Nt-proANP and C-ANP. Eur J Clin Invest 32: 545-548.
  60. Bartkowiak R, Wozakowska-Kaplon B, Janiszewska G (2010) Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion. Kariol Pol 68: 48-54.
  61. Rubattu S, Barbato A, Marchitti S, Iacone R, Di Castro S, et al. (2010) Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy. J Hypertens 28: 1638-1645.
  62. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, et al. (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40: 976-982.
  63. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, et al. (2005) Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 7: 81-86.
  64. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, Sokolowska B, Hausmanowa-Petrusewicz I (2011) Osteopontin--a fibrosis-related marker--in dilated cardiomyopathy in patients with Emery-Dreifuss muscular dystrophy. Scand J Clin Lab Invest 71: 658-662.
  65. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, Sokolowska B, Hausmanowa-Petrusewicz I (2011) Circulating tenascin -C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin Chim Acta 412: 1533-1538.
  66. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, SokoÅowska B, Hausmanowa-Petrusewicz I (2009) Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients. Acta Biochim Pol 56: 717-722.
Citation: Niebroj-Dobosz IM, Sokolowska B, Madej-Pilarczyk A, Marchel M, Hausmanowa-Petrusewicz I (2012) Natriuretic Peptides Assessment in Dilated Cardiomyopathy in Patients with Emery-Dreifuss Muscular Dystrophy. J Clin Exp Cardiolog 3:206.

Copyright: © 2012 Niebroj-Dobosz IM et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.